Klaria Pharma Holding AB has the GF Score of 28, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Klaria Pharma Holding AB
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Klaria Pharma Holding AB (FRA:6FN) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Klaria Pharma Holding AB GF Score Related Terms
FRA:6FN vs ZTS, UTHR: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klaria Pharma Holding AB GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's GF Score distribution charts can be found below:
* The bar in red indicates where Klaria Pharma Holding AB's GF Score falls into.
Klaria Pharma Holding AB (FRA:6FN) has a GF Score of 28 as of Jul. 01, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Klaria Pharma Holding AB and its competitors. This is 27% above median its historical median of 22.00. Over the past decade, Klaria Pharma Holding AB's GF Score has ranged from 10.00 to 45.00.
Is Klaria Pharma Holding AB's GF Score too high?
Klaria Pharma Holding AB's current GF Score of 28 is 27% above median its 10-year median of 22.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 45.00. Overall, Klaria Pharma Holding AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's GF Score compare to ZTS and UTHR?
Klaria Pharma Holding AB's GF Score of 28 can be compared against companies in the Drug Manufacturers industry. Historically, Klaria Pharma Holding AB's own GF Score has ranged from 10.00 to 45.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Klaria Pharma Holding AB and its competitors. Klaria Pharma Holding AB's current GF Score is 28, which is 27% above median its own 10-year median of 22.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.06 — trading 104.3% above its estimated fair value. The current GF Score is 28, which is 27% above median its 10-year median of 22.00. Klaria Pharma Holding AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current GF Score is 28 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?
Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued.
The current stock price of €0.06 is trading 104.3% above its estimated GF Value™ of €0.03.
GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.
Key valuation signals for FRA:6FN:
GF Score: 28 (27% above median its 10-year median of 22.00)
GF Value™: €0.03 vs. price of €0.06 (104.3% above fair value)
No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
28GF Score
Get the complete analysis for FRA:6FN
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FN has been successfully added to your 